WO2019240677A3 - Composition of vitamin c and vitamin e with rifampicin for the treatment of all infected wounds and all dermatological problems either infected or at risk of being infected - Google Patents
Composition of vitamin c and vitamin e with rifampicin for the treatment of all infected wounds and all dermatological problems either infected or at risk of being infected Download PDFInfo
- Publication number
- WO2019240677A3 WO2019240677A3 PCT/TR2018/000016 TR2018000016W WO2019240677A3 WO 2019240677 A3 WO2019240677 A3 WO 2019240677A3 TR 2018000016 W TR2018000016 W TR 2018000016W WO 2019240677 A3 WO2019240677 A3 WO 2019240677A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infected
- vitamin
- rifampicin
- risk
- composition
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title abstract 3
- 229960001225 rifampicin Drugs 0.000 title abstract 3
- 206010052428 Wound Diseases 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 229940088594 vitamin Drugs 0.000 title 1
- 229930003231 vitamin Natural products 0.000 title 1
- 235000013343 vitamin Nutrition 0.000 title 1
- 239000011782 vitamin Substances 0.000 title 1
- 150000003722 vitamin derivatives Chemical class 0.000 title 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 206010016717 Fistula Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003890 fistula Effects 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition of vitamin C and vitamin E with rifampicin, which has a broad activity spectrum and may be used for any wound, cut, fistula, and fissure that are either infected or at risk of being infected, as well as for any dermatologic purulent inflammation that is either infected or at risk of being infected and is sensitive to rifampicin, without using a plurality of different antibacterial preparations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/03602 | 2017-03-09 | ||
| TR201703602 | 2017-03-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2019240677A2 WO2019240677A2 (en) | 2019-12-19 |
| WO2019240677A3 true WO2019240677A3 (en) | 2020-02-27 |
Family
ID=68842982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2018/000016 WO2019240677A2 (en) | 2017-03-09 | 2018-03-06 | Composition of vitamin c and vitamin e with rifampicin for the treatment of all infected wounds and all dermatological problems either infected or at risk of being infected |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019240677A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312866A (en) * | 1979-07-10 | 1982-01-26 | Dr. L. Zambeletti S.P.A. | Use of rifamycin SV and its related salts in the treatment of rheumatoid arthritis, and related formulations suited for the purpose |
| CN102579327A (en) * | 2012-02-12 | 2012-07-18 | 王伟志 | Rifamycin SV sodium injection and preparation method thereof |
| RU2012125482A (en) * | 2012-06-19 | 2013-12-27 | Муниципальное бюджетное учреждение здравоохранения "Клиническая поликлиника N 5" г. Кемерово | EXTERNAL MEDICINE FOR TREATMENT IN Wounds contaminated with microflora |
-
2018
- 2018-03-06 WO PCT/TR2018/000016 patent/WO2019240677A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312866A (en) * | 1979-07-10 | 1982-01-26 | Dr. L. Zambeletti S.P.A. | Use of rifamycin SV and its related salts in the treatment of rheumatoid arthritis, and related formulations suited for the purpose |
| CN102579327A (en) * | 2012-02-12 | 2012-07-18 | 王伟志 | Rifamycin SV sodium injection and preparation method thereof |
| RU2012125482A (en) * | 2012-06-19 | 2013-12-27 | Муниципальное бюджетное учреждение здравоохранения "Клиническая поликлиника N 5" г. Кемерово | EXTERNAL MEDICINE FOR TREATMENT IN Wounds contaminated with microflora |
Non-Patent Citations (1)
| Title |
|---|
| AWODELE, O. ET AL.: "Protective effect of vitamin C and or vitamin E on micronuclei induction by rifampicin in mice", TANZANIA JOURNAL OF HEALTH RESEARCH, vol. 12.2, 2010, pages 150 - 154, XP055687101 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019240677A2 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3862009A4 (en) | Composition for skin regeneration and wound healing, comprising induced exosomes | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| EP3955839A4 (en) | Devices, systems and methods for the treatment of abnormal tissue | |
| BR112018008601A2 (en) | compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer | |
| EP3466447A4 (en) | Topical pharmaceutical composition for treating multiple forms of skin wounds and manufacturing method thereof | |
| EP3873442A4 (en) | Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| IL290339A (en) | Topical formulations comprising cannabidiol, method of preparing the compositions and use thereof | |
| EP3801463A4 (en) | Therapeutic compositions for enhanced healing of wounds and scars | |
| WO2014179318A3 (en) | Antimicrobials and methods of use thereof for wound healing | |
| MX2019001633A (en) | Silk-derived protein for treating inflammation. | |
| EP4045024A4 (en) | Transdermal delivery of cannabidiol | |
| EP3920844A4 (en) | Methods and devices to reduce the risk of infection | |
| WO2012024399A3 (en) | Compositions comprising paulownin and/or paulownia extracts and uses thereof | |
| EP3964520A4 (en) | Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising same as active ingredient | |
| EP3327000A4 (en) | Novel compound having blt inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | |
| WO2017034451A8 (en) | Surgical bandage with stabilizing elements | |
| EP3957314A4 (en) | Use of extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage | |
| WO2018094023A3 (en) | Cyclic dipeptides and wound healing | |
| EP4005572A4 (en) | Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer | |
| IL277913A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and niethods of treatment | |
| WO2019240677A3 (en) | Composition of vitamin c and vitamin e with rifampicin for the treatment of all infected wounds and all dermatological problems either infected or at risk of being infected | |
| EP4023234A4 (en) | Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer | |
| MX2017016226A (en) | Pharmaceutical compositions comprising polyalkylene glycol derivatives. | |
| EP3697433A4 (en) | Topical composition for improved healing of open wounds | |
| EP3789019A4 (en) | Composition for prevention or treatment of skin infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18922872 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18922872 Country of ref document: EP Kind code of ref document: A2 |